Nasal Drug and Vaccine Delivery: Opportunities, Advantages and Limitations of Nanomaterials
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (10 December 2022) | Viewed by 6022
Special Issue Editor
Interests: nanoparticles; bionanomaterials; vaccine adjuvants; polymers; exosomes; hepatitis; therapeutic vaccines; prophylactic vaccines; immunotoxicity; immunotolerance; safety-by-design; quality-by-design; immune response
Special Issue Information
Dear Colleagues,
The advantages of the nasal administration route are well known among the scientific community for both local and systemic drugs. Its ease of access and consequent high patient compliance are attractive features, but the avoidance of the gastrointestinal tract’s harsh conditions and first-pass metabolism surpass the convenience of oral administration. In the vaccine field, the nasal delivery of antigens carries additional advantages, as it is implicated in the generation of a mucosal immune response, which is particularly important for preventing infection by airborne pathogens.
Continuous advances in the nanotechnology field, particularly related to polymeric nanobiomaterials, are greatly associated with the development of new particulate delivery systems for the nasal delivery of drugs and antigens.
This Special Issue welcomes original research papers and review articles highlighting recent developments and innovations in the area of nasal drug delivery. Articles covering the synthesis, development, physicochemical characterization and in vitro and in vivo evaluation of new drug/vaccine delivery systems based on polymeric nanomaterials, designed for the nasal route of administration, are welcomed.
We look forward to receiving your contributions.
Dr. Sandra Jesus
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nasal drug and vaccine delivery
- nanoparticles
- vaccine adjuvants
- polymeric nanobiomaterials
- safety-by-design
- quality-by-design
- immunotoxicity and Immunotolerance
- immune response
- nasal mucosa permeability
